Please note, this OEL/ADE monograph also applies to nafamostat mesylate (CAS RN 82956-11-4). Nafamostat mesylate, also known as nafamostat mesilate, (6-amidino-2-naphthyl-pguanidinobenzoate dimethanesulfonate) is the mesylate salt form of nafamostat, a broadspectrum, synthetic serine protease inhibitor, with anticoagulant, anti-inflammatory, mucus clearing, potential antitumor, and potential antiviral activities (2, 3, 4). Nafamostat is used in Asian countries to improve acute symptoms of pancreatitis (acute pancreatitis, acute exacerbation phase of chronic pancreatitis, postoperative acute pancreatitis, acute pancreatitis after pancreatography, traumatic pancreatitis), treat disseminated intravascular coagulation (DIC), and prevent clotting of perfusing blood in extracorporeal blood circuit. Recently, in vitro studies revealed that nafamostat mesylate has antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and an antiinflammatory and anticoagulation effect. Clinical studies are currently ongoing to evaluate the clinical efficacy of nafamostat mesylate in adult patients hospitalized with COVID-19 pneumonia.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), and to obtain the following information:
To order an OEL/ADE monograph for Nafamostat, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’s OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.